Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Troponin I-guided candesartan and carvedilol for prevention of anthracycline cardiotoxicity
2017-000896-99Phase 2Unknown
- Sponsor
- University of Edinburgh
- Start
- May 2018
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of candesartan and carvedilol in chemotherapy-induced cardiotoxicity (CIC) and left ventricular systolic dysfunction (LVSD) (2 arms), sponsored by University of Edinburgh. Primary endpoint: Change in left ventricular ejection fraction. Status: unknown.
02
Drugs
candesartancarvedilol
03
Conditions
chemotherapy-induced cardiotoxicity (CIC)left ventricular systolic dysfunction (LVSD)
Beyond the preview
Go deeper on 2017-000896-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000896-99.